




**Supplementary material**



**Supplementary Figure S1.** Demographics in the serological screening of population without registered SARS-CoV-2 infections: demographic parameters of participants found positive for anti-SARS-CoV-2 IgG in each investigated group compared to general demographic parameters of the group. Antibodies were identified in blood samples after separation of blood sera by clotting and centrifugation. Microblot-array testing was applied to determine IgG level in each participants and positive/negative result was qualified according to the validated test.




**Supplementary Figure S2.** Demographics in the serological screening of population without registered SARS-CoV-2 infections: demographic parameters of each investigated group compared to general demographic parameters of the whole country.



- demographic parameters of the Patients hospitalized due to COVID-19
- demographic parameters of the Polish population (general)

**Supplementary Figure S3.** Demographics in patients hospitalized due to COVID-19



**Supplementary Figure S4.** IgG specific to SARS-CoV-2 in non-vaccinated patients hospitalized due to COVID-19: female and male comparison. Anti-NCP- antibodies specific to nucleocapsid protein N, anti-RBD- antibodies specific to receptor binding domain within spike protein S1 region. Antibodies were identified in blood samples after separation of blood sera by clotting and centrifugation. Microblot-array testing was applied to determine IgG level (U/ml). Median values are presented (dash), with quartiles 1 and 3 (boxes), and minimum/maximum values (whiskers);  $p > 0.05$  by Welsh test

**Supplementary Table S1.** Distributions of quantitative variables of measurements for IgG specific to SARS-CoV-2 NCP and RBD in: Group 1: anti-NCP IgG negative, non-vaccinated; Group 2: anti-NCP IgG negative, vaccinated; Group 3: anti-NCP IgG positive, non-vaccinated; Group 4: anti-NCP IgG positive, vaccinated. NCP – nucleocapsid protein, RBD – receptor binding protein

Group	Antibody	Date of the study	N	Min	Q25%	Median	Q75%	Max	Range	Average
1	NCP	May	38	0	0	5.211	17.27	107.3	107.3	13.11
		December	38	0	13.82	20.96	416.5	986.2	986.2	219
	RBD	May	38	0	0	0.691	6.769	120	120	6.172
		December	38	19.77	38.09	58.61	278.8	976.7	956.9	207.6
2	NCP	May	29	0	0.0605	8.425	39.6	170.7	170.7	27.53
		December	29	5.701	14.55	21.6	26.16	400	394.3	51.78
	RBD	May	29	0	0	0.398	7.759	64.88	64.88	7.461
		December	29	59.99	457.1	809.6	943.7	987.2	927.2	696.6
3	NCP	May	25	317	752	929	989.9	1343	1026	844.6
		December	25	0	41.91	158.6	265.1	818.9	818.9	196.7
	RBD	May	25	11.73	305.2	922.5	982.9	1221	1209	683.2
		December	25	5.202	112	202.7	492.1	935.5	930.3	308.9
4	NCP	May	17	238.1	553.9	862.1	969.6	1279	1041	774
		December	17	19.61	35.1	91.53	133.6	476.9	457.2	118.8
	RBD	May	17	0	220.4	558.4	805.3	1221	1221	518.5
		December	17	461.5	759	941.6	972.9	988.5	527	862

Results are given as U/ml. Q25% and Q75% - 1. and 3. Quantile.

**Supplementary Table S2.** Distributions of quantitative variables – IgG specific to SARS-CoV-2 NCP, RBD and Spike S2 in: non-vaccinated patients hospitalized due to COVID-19 and vaccinated control group

		N	Min	Q25%	Median	Q75%	Max	Average
non-vaccinated	NP	95	0	469.3	957.1	988	1418	755.1
	RBD	95	0	830	940.4	972.5	1297	790.9
male non-vaccinated	NP	56	0	567	950.3	999.5	1229	776.3
	RBD	56	0	858.5	946	978.9	1283	797.1
female non-vaccinated	NP	40	0	200.9	957.7	974.5	1418	729.8
	RBD	40	0	823.2	932.1	965.2	1297	786.7
Mild anti-NCP	D5	5	0	4.527	42.87	565.9	944.1	236.7
	D10	11	0	3.067	483.3	957.2	964	474.6
	D15	17	16.64	189.1	942.9	971.5	1229	657.8
	D30	6	773.3	786	918.8	969.2	1002	893.5
	D90	2	988	988	988.1	988.1	988.1	988.1
Moderate anti-NCP	D10	4	850.4	877.3	961.3	967.7	968.7	935.4
	D15	12	469.3	972.8	980.8	1018	1418	994.9
	D30	8	950.2	974.2	1002	1057	1182	1022
	D90	7	817.9	950.5	966.4	988.5	988.7	952.1

Severe anti-NCP	D10	5	0	0	58.18	693.2	945.1	288.9
	D15	7	33.99	65.59	841.3	1066	1102	698.2
	D30	4	1002	1004	1059	1145	1157	1069
	D90	4	868.8	881.4	941.1	981.2	987.2	934.6
Mild anti-RBD	D5	5	47.38	69.21	140.2	927.1	944.1	426.6
	D10	11	0	96.13	501.9	957.2	964	516.9
	D15	17	0	610.1	930.1	952.2	1283	771.3
	D30	6	883.7	903.9	940.4	988.6	1004	943.8
	D90	2	970.6	970.6	973.8	976.9	976.9	973.8
Moderate anti-RBD	D10	4	830	835.1	878.3	954.1	970.1	889.2
	D15	12	675.2	916.8	963.9	1015	1297	966.7
	D30	8	882.9	932.2	1005	1056	1112	999.8
	D90	7	915.3	944.6	959	977.6	988.7	957.9
Severe Anti-RBD	D10	5	0	27.71	138.9	718.7	972.5	326.3
	D15	7	0	92.36	936.4	1186	1250	760.6
	D30	4	1002	1002	1013	1078	1096	1031
	D90	4	906.8	909.3	940.2	967.3	968.6	938.9

Results are given as U/ml. Q25% and Q75% - 1. and 3. Quantile. Day 5.10.15.30.90 from the onset of the infection.

**Supplementary Table S3.** Number and percentage of smokers and allergies in studied groups.

	Group 1 (N=38) negative for anti- NCP IgG in May. non-vaccinated	Group 2 (N=29) negative for anti- NCP IgG in May. vaccinated	Group 3 (N=25) positive for anti- NCP IgG in May. non-vaccinated	Group 4 (N=17) positive for anti- NCP IgG in May. vaccinated
Allergy	11 (29%)	7 (24%)	4 (16%)	6 (35%)
Smokers	11 (29%)	7 (24%)	8 (32%)	3 (18%)

**Supplementary Table S4.** Distribution of BMI index in the study groups

	Min	Q1	Media n	Q3	Max	Mean	Std. Deviation	Std. Error of Mean
Group 1 (N=38) negative for anti-NCP IgG in May. non-vaccinated	19.05	21.92	25.57	29.36	35.32	25.84	4.58	0.74
Group 2 (N=29) negative for anti-NCP IgG in May. vaccinated	17.1	21.81	23.83	28.36	33.79	24.79	4.56	0.85
Group 3 (N=25) positive for anti-NCP IgG in May. non-vaccinated	20.29	22.81	27.77	30.2	35.16	27.05	4.59	0.92

Group 4 (N=17) positive for anti-NCP IgG in May. vaccinated	17.36	20.24	23.53	28.42	38.58	24.74	5.53	1.34
Q25% and Q75% - 1. and 3. Quantile								

**Supplementary Table S5.** T-test between each time point sample for anti-RBD IgG titres. P-values obtained for each set of groups were adjusted for multiple hypothesis.

Anti-RBD					
Mild	D5	D10	D15	D30	D90
D5	-	> 0.1	> 0.1	> 0.1	> 0.1
D10	> 0.1	-	<b>&lt; 0.01</b>	<b>&lt; 0.05</b>	<b>&lt; 0.05</b>
D15	> 0.1	<b>&lt; 0.01</b>	-	> 0.1	> 0.1
D30	> 0.1	<b>&lt; 0.05</b>	> 0.1	-	> 0.1
D90	> 0.1	<b>&lt; 0.05</b>	> 0.1	> 0.1	-
Moderate	D5	D10	D15	D30	D90
D5	-	-	-	-	-
D10	-	-	<b>&lt; 0.001</b>	<b>&lt; 0.05</b>	> 0.1
D15	-	<b>&lt; 0.001</b>	-	> 0.1	> 0.1
D30	-	<b>&lt; 0.05</b>	> 0.1	-	> 0.1
D90	-	> 0.1	> 0.1	> 0.1	-
Severe	D5	D10	D15	D30	D90
D10	> 0.1	-	> 0.1	<b>&lt; 0.05</b>	> 0.1
D15	> 0.1	> 0.1	-	> 0.1	> 0.1
D30	> 0.1	<b>&lt; 0.05</b>	> 0.1	-	<b>0.1 &gt; p &gt; 0.05</b>
D90	> 0.1	> 0.1	> 0.1	<b>0.1 &gt; p &gt; 0.05</b>	-

**Supplementary Table S6.** T-test between each time point sample for anti-NCP IgG titres.

Anti -NCP					
Mild	D5	D10	D15	D30	D90
D5	-	> 0.1	> 0.1	<b>0.1 &gt; p &gt; 0.05</b>	> 0.1
D10	> 0.1	-	> 0.1	<b>0.1 &gt; p &gt; 0.05</b>	<b>0.1 &gt; p &gt; 0.05</b>
D15	> 0.1	> 0.1	-	> 0.1	> 0.1
D30	<b>0.1 &gt; p &gt; 0.05</b>	<b>0.1 &gt; p &gt; 0.05</b>	> 0.1	-	> 0.1
D90	> 0.1	<b>0.1 &gt; p &gt; 0.05</b>	> 0.1	> 0.1	-
Moderate	D5	D10	D15	D30	D90
D5	-	-	-	-	-
D10	-	-	> 0.1	> 0.1	> 0.1

D15	-	> 0.1	-	> 0.1	> 0.1
D30	-	> 0.1	> 0.1	-	< 0.05
D90	-	> 0.1	> 0.1	< 0.05	-
Severe	D5	D10	D15	D30	D90
D10	<b>0.1 &gt; p &gt; 0.05</b>	-	> 0.1	<b>0.1 &gt; p &gt; 0.05</b>	> 0.1
D15	> 0.1	> 0.1	-	> 0.1	> 0.1
D30	> 0.1	<b>0.1 &gt; p &gt; 0.05</b>	> 0.1	-	< 0.05
D90	> 0.1	> 0.1	> 0.1	< 0.05	-